Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Tomuleasa, Ciprian  [Clear All Filters]
2024
Kiladjian J-J, Marin FFerrer, Al-Ali HKathrin, Alvarez-Larran A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan A-M, et al. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Ann Hematol. 2024.
2023
Tigu ABogdan, Constantinescu CSorin, Teodorescu P, Kegyes D, Munteanu R, Feder R, Peters M, Pralea I, Iuga C, Cenariu D, et al. Design and preclinical testing of an anti-CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia. J Cell Mol Med. 2023.
Cenariu D, Rus I, Bergthorsson JThor, Grewal R, Cenariu M, Greiff V, Tigu A-B, Dima D, Selicean C, Petrushev B, et al. Flow Cytometry of CD5-Positive Hairy Cell Leukemia. Mol Diagn Ther. 2023.
Constantinescu C, Constantinescu R, Bergthorsson JThor, Greiff V, Tanase A, Colita A, Gulei D, Tomuleasa C. Pitfalls in patenting academic CAR-T cells therapy. Expert Opin Ther Pat. 2023.
Kegyes D, Gulei D, Drula R, Cenariu D, Tigu B, Dima D, Tanase A, Badelita S, Buzoianu A-D, Ciurea S, et al. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. Blood Rev. 2023:101100.
Kegyes D, Jitaru C, Ghiaur G, Ciurea S, Hoelzer D, Tomuleasa C, Gale RPeter. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia. Blood Rev. 2023:101042.
Cismaru CAndrei, Tomuleasa C, Jurj A, Chira S, Isachekcu E, Cismaru G, Gherman LMadalina, Gulei D, Munteanu R, Neagoe IBerindan. Synergistic Effect of Human Chorionic Gonadotropin and Granulocyte Colony Stimulating Factor in the Mobilization of HSPCs Improves Overall Survival After PBSCT in a Preclinical Murine Model. Are We Far Enough for Therapy?. Stem Cell Rev Rep. 2023.
2020
Mester A, Irimie AIulia, Tanase A, Tranca S, Campian RSeptimiu, Tomuleasa C, Dima D, Piciu A, Lucaciu O. Periodontal disease might be a risk factor for graft versus host disease. A systematic review. Crit Rev Oncol Hematol. 2020;147:102878.
2019
Tatar A-S, Jurj A, Tomuleasa C, Florea A, Berindan-Neagoe I, Cialla-May D, Popp J, Astilean S, Boca S. CD19-targeted, Raman tagged gold nanourchins as theranostic agents against acute lymphoblastic leukemia. Colloids Surf B Biointerfaces. 2019;184:110478.
2016
Tanase A, Tomuleasa C, Marculescu A, Bardas A, Colita A, Orban C, Ciurea SOctavian. Haploidentical Donors: Can Faster Transplantation Be Life-Saving for Patients with Advanced Disease?. Acta Haematol. 2016;135(4):211-216.
Gaballa S, Ge I, Fakih REl, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, et al. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016.
2014
Rani B, Cao Y, Malfettone A, Tomuleasa C, Fabregat I, Giannelli G. Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2014;20(15):4128-4140.